NXTC
NextCure, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.12
−12.48%Price chart
Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5
Key dataNov 5, 2026
Open$5.55
From 52W high−64.12%
Volume23856.00
Market cap$23.44M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 5, 2026
Open
$5.55
From 52W high
−64.12%
Volume
23856.00
Market cap
$23.44M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
P/E (TTM)
—
RSI (14)
45.8
MomentumView details →
1D Return
−12.48%
YTD Return
−61.38%
SummaryUpdated Jun 1, 2026
NextCure, Inc. (NASDAQ:NXTC) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Beltsville, Maryland. The company went public in May 2019 and focuses on discovering and developing novel immunotherapies to treat cancer and other immune-related diseases. NextCure's approach centers on restoring normal immune function through targeted immunomodulation, representing a specialized segment within the broader cancer immunotherapy field.
Similar companies
Latest newsMore news →
NextCure said Chief Medical Officer Dr. Udayan Guha will depart effective October 31, 2026, and will receive severance benefits under his employment agreement, with additional change-in-control severance conditional on the merger closing.7d agoNextCure, Inc. amended its lease agreement, accelerating the lease expiration to December 31, 2027, terminating rent obligations as of September 1, 2026, and paying a lump sum of $758,648 while forfeiting a $39,292.70 security deposit.64d agoXcellon Biologics acquires a GMP manufacturing facility from NextCure, becoming an end-to-end CRDMO for next-generation bioconjugates and complex biologics.88d ago